Progressive supranuclear palsy: Clinical and genetic aspects

Current Opinion in Neurology

Volumn 15, Issue 4, 2002, Pages 429-437

  Pastor, Pau ^a   Tolosa, Eduardo ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Diagnosis; Genetics; Progressive supranuclear palsy; Tau gene

Indexed keywords

BIOLOGICAL MARKER; TAU PROTEIN;

CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; GENE MUTATION; GENETICS; HUMAN; LABORATORY TEST; PATHOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; REVIEW;

HUMANS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 0036316037     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200208000-00005     Document Type: Review

References (78)

1. Genetic evidence for the involvement of tau in progressive supranuclear palsy
2. Tau protein pathology in neurodegenerative diseases
3. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease
4. Tau mutations cause frontotemporal dementias
5. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization
6. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease
7. Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau
8. Progressive supranuclear palsy
9. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms
10. Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy
11. Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: Differentiation from progressive supranuclear palsy
12. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy
13. Recent advances in the understanding of tau protein and movement disorders
14. Diagnosis and management of progressive supranuclear palsy
15. Progressive supranuclear palsy
16. Prevalence and natural history of progressive supranuclear palsy
17. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study
18. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK
19. Neuropsychiatric aspects of progressive supranuclear palsy
20. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease
21. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy
22. Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology
23. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders
24. Neuropathological correlates of dysarthria in progressive supranuclear palsy
25. Measurement of the midbrain diameter on routine magnetic resonance imaging: A simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy
26. Abnormal signals on proton density-weighted MRI of the superior cerebellar peduncle in progressive supranuclear palsy
27. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes
28. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy
29. Performance on the PD test battery by relatives of patients with progressive supranuclear palsy
30. Donepezil in the treatment of progressive supranuclear palsy
31. Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy
32. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy
33. Familial progressive supranuclear palsy. Description of a pedigree and review of the literature
34. Clinical genetics of familial progressive supranuclear palsy
35. New form of familial Parkinson-dementia syndrome: Clinical and pathologic findings
36. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration
37. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration
38. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases
39. Progressive supranuclear gaze palsy is in linkage disequilibrium with the tau and not the alpha-synuclein gene
40. Direct genetic evidence for involvement of tau in progressive supranuclear palsy
41. Significant changes in the tau A0 and A3 alleles in progressive supranuclear palsy and improved genotyping by silver detection
42. Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: Implication for progressive supranuclear palsy
43. Progressive supranuclear palsy: Earlier age of onset in patients with the tau protein A0/A0 genotype
44. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy
45. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy
46. Association of an extended haplotype in the tau gene with progressive supranuclear palsy
47. Mutational analysis of the tau gene in progressive supranuclear palsy
48. An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy
49. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease
50. Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans
51. Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy
52. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements
53. Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion
54. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17
55. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy
56. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
57. Further extension of the H1 haplotype associated with progressive supranuclear palsy
58. A genomic sequence analysis of the mouse and human microtubule-associated protein tau
59. Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE
60. Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy
61. Mitochondrial dysfunction in progressive supranuclear palsy
62. New insights into progressive supranuclear palsy
63. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy
64. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism
65. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
66. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
67. From genotype to phenotype: A clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation
68. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy
69. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia
70. FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10
71. Tau pathology: A marker of neurodegenerative disorders
72. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations
73. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene
74. Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells
75. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies
76. The tau gene in progressive supranuclear palsy: Exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases
77. Tau is a candidate gene for chromosome 17 frontotemporal dementia
78. The tau gene A0 allele and progressive supranuclear palsy